Experts: GLP-1 drugs beyond weight loss
Ozempic and Wegovy are widely used to support weight loss and manage diabetes. But could this class of drugs, known as GLP-1 receptor agonists, also help treat heart failure, liver disease and even addiction?
by researchers at 蘑菇短视频 and the Lady Davis Institute for Medical Research at the Jewish General Hospital takes a closer look at their growing list of potential uses beyond diabetes and obesity.
Published in eClinicalMedicine, the narrative review brings together evidence from dozens of studies to assess how these medications are being used, where they show promise and what concerns remain.
The authors are available to speak on topics including:
- The benefits and risks of GLP-1 drugs for weight loss
- Emerging uses including heart and kidney disease, sleep apnea, osteoarthritis, Alzheimer鈥檚, Parkinson鈥檚 and addiction
- Questions about long-term safety (e.g. gallbladder issues, psychiatric effects, vision risks)
- Cost and access concerns in publicly funded health systems
Available Experts:
Areesha Moiz, Clinical Research Assistant, Centre of Clinical Epidemiology, Lady Davis Institute, Jewish General Hospital
areesha.moiz [at] mail.mcgill.ca (English)
Dr. Mark Eisenberg, James 蘑菇短视频 Professor, Department of Medicine, 蘑菇短视频, Senior Investigator, Lady Davis Institute, Jewish General Hospital
mark.eisenberg [at] mcgill.ca (English, French)
